- Home
- NUWE vs ONVO Comparison
NUWE vs ONVO Comparison
Compare NUWE & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- ONVO
- Stock Information
- Founded
- NUWE 1999
- ONVO 2007
- Country
- NUWE United States
- ONVO United States
- Employees
- NUWE N/A
- ONVO N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NUWE Health Care
- ONVO Health Care
- Exchange
- NUWE Nasdaq
- ONVO Nasdaq
- Market Cap
- NUWE 5.2M
- ONVO 5.3M
- IPO Year
- NUWE N/A
- ONVO N/A
- Fundamental
- Price
- NUWE $1.30
- ONVO $0.37
- Analyst Decision
- NUWE Strong Buy
- ONVO
- Analyst Count
- NUWE 1
- ONVO 0
- Target Price
- NUWE $17.00
- ONVO N/A
- AVG Volume (30 Days)
- NUWE 1.1M
- ONVO 99.1K
- Earning Date
- NUWE 03-11-2025
- ONVO 02-19-2025
- Dividend Yield
- NUWE N/A
- ONVO N/A
- EPS Growth
- NUWE N/A
- ONVO N/A
- EPS
- NUWE N/A
- ONVO N/A
- Revenue
- NUWE $8,969,000.00
- ONVO $122,000.00
- Revenue This Year
- NUWE $2.18
- ONVO $59.08
- Revenue Next Year
- NUWE $25.75
- ONVO $18.24
- P/E Ratio
- NUWE N/A
- ONVO N/A
- Revenue Growth
- NUWE 3.66
- ONVO N/A
- 52 Week Low
- NUWE $0.92
- ONVO $0.32
- 52 Week High
- NUWE $26.95
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- NUWE 52.78
- ONVO 49.60
- Support Level
- NUWE $1.17
- ONVO $0.33
- Resistance Level
- NUWE $1.48
- ONVO $0.40
- Average True Range (ATR)
- NUWE 0.09
- ONVO 0.03
- MACD
- NUWE 0.01
- ONVO 0.00
- Stochastic Oscillator
- NUWE 45.45
- ONVO 61.25
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical device company. Its solutions includes Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidney monitoring system that continuously measures urine output and flows, automatically displaying real-time data to the medical staff.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.